BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 17548792)

  • 1. Chemopreventive efficacy of silymarin in skin and prostate cancer.
    Deep G; Agarwal R
    Integr Cancer Ther; 2007 Jun; 6(2):130-45. PubMed ID: 17548792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skin cancer chemopreventive effects of a flavonoid antioxidant silymarin are mediated via impairment of receptor tyrosine kinase signaling and perturbation in cell cycle progression.
    Ahmad N; Gali H; Javed S; Agarwal R
    Biochem Biophys Res Commun; 1998 Jun; 247(2):294-301. PubMed ID: 9642119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silymarin and skin cancer prevention: anti-inflammatory, antioxidant and immunomodulatory effects (Review).
    Katiyar SK
    Int J Oncol; 2005 Jan; 26(1):169-76. PubMed ID: 15586237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer chemoprevention by silibinin: bench to bedside.
    Singh RP; Agarwal R
    Mol Carcinog; 2006 Jun; 45(6):436-42. PubMed ID: 16637061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cancer chemopreventive agent silibinin, targets mitogenic and survival signaling in prostate cancer.
    Singh RP; Agarwal R
    Mutat Res; 2004 Nov; 555(1-2):21-32. PubMed ID: 15476849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels.
    Singh RP; Dhanalakshmi S; Tyagi AK; Chan DC; Agarwal C; Agarwal R
    Cancer Res; 2002 Jun; 62(11):3063-9. PubMed ID: 12036915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiproliferative and apoptotic effects of silibinin in rat prostate cancer cells.
    Tyagi A; Bhatia N; Condon MS; Bosland MC; Agarwal C; Agarwal R
    Prostate; 2002 Nov; 53(3):211-7. PubMed ID: 12386921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms and preclinical efficacy of silibinin in preventing skin cancer.
    Singh RP; Agarwal R
    Eur J Cancer; 2005 Sep; 41(13):1969-79. PubMed ID: 16084079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticancer potential of silymarin: from bench to bed side.
    Agarwal R; Agarwal C; Ichikawa H; Singh RP; Aggarwal BB
    Anticancer Res; 2006; 26(6B):4457-98. PubMed ID: 17201169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dietary supplementation with silymarin inhibits 3,2'-dimethyl-4-aminobiphenyl-induced prostate carcinogenesis in male F344 rats.
    Kohno H; Suzuki R; Sugie S; Tsuda H; Tanaka T
    Clin Cancer Res; 2005 Jul; 11(13):4962-7. PubMed ID: 16000596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft.
    Singh RP; Deep G; Blouin MJ; Pollak MN; Agarwal R
    Carcinogenesis; 2007 Dec; 28(12):2567-74. PubMed ID: 17916909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model.
    Raina K; Blouin MJ; Singh RP; Majeed N; Deep G; Varghese L; Glodé LM; Greenberg NM; Hwang D; Cohen P; Pollak MN; Agarwal R
    Cancer Res; 2007 Nov; 67(22):11083-91. PubMed ID: 18006855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toward the definition of the mechanism of action of silymarin: activities related to cellular protection from toxic damage induced by chemotherapy.
    Comelli MC; Mengs U; Schneider C; Prosdocimi M
    Integr Cancer Ther; 2007 Jun; 6(2):120-9. PubMed ID: 17548791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helix forming oligonucleotide directed against androgen receptor.
    Zhang Y; Ma Y; Lu HP; Gao JH; Liang CS; Liu CZ; Zou JT; Wang HQ
    Chin Med J (Engl); 2008 Nov; 121(22):2284-9. PubMed ID: 19080333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silibinin inhibits cell growth and induces apoptosis by caspase activation, down-regulating survivin and blocking EGFR-ERK activation in renal cell carcinoma.
    Li L; Gao Y; Zhang L; Zeng J; He D; Sun Y
    Cancer Lett; 2008 Dec; 272(1):61-9. PubMed ID: 18723275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flavonoid antioxidant silymarin and skin cancer.
    Singh RP; Agarwal R
    Antioxid Redox Signal; 2002 Aug; 4(4):655-63. PubMed ID: 12230878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A potent indole-3-carbinol derived antitumor agent with pleiotropic effects on multiple signaling pathways in prostate cancer cells.
    Weng JR; Tsai CH; Kulp SK; Wang D; Lin CH; Yang HC; Ma Y; Sargeant A; Chiu CF; Tsai MH; Chen CS
    Cancer Res; 2007 Aug; 67(16):7815-24. PubMed ID: 17699787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemopreventive effect of silymarin on liver pathology in HBV X protein transgenic mice.
    Wu YF; Fu SL; Kao CH; Yang CW; Lin CH; Hsu MT; Tsai TF
    Cancer Res; 2008 Mar; 68(6):2033-42. PubMed ID: 18339886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of mammary carcinogenesis in two rodent models by silymarin dietary supplements.
    Malewicz B; Wang Z; Jiang C; Guo J; Cleary MP; Grande JP; Lü J
    Carcinogenesis; 2006 Sep; 27(9):1739-47. PubMed ID: 16597642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silymarin and hepatocellular carcinoma: a systematic, comprehensive, and critical review.
    Mastron JK; Siveen KS; Sethi G; Bishayee A
    Anticancer Drugs; 2015 Jun; 26(5):475-86. PubMed ID: 25603021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.